Dr. Robert Marx will be Presenting 2 Lectures During Pikos Symposium
Practical Applications of Stem Cells, Osteoprogenitor Cells, and Growth Factors in Bone Regeneration – Thursday, October 15, 2020, 1:45 pm – 3:45 pm
In-Situ Tissue Engineering (ITSE) is in frequent use today. Access to stem cells, osteoprogenitor cells, and growth factors can be obtained from quality Platelet Rich Plasma (PRP) or Bone Marrow Aspirates (BMA). This allows the clinicians to regenerate 100% viable patient-specific bone for implant placements, filling in existing bone defects, cystic defects and to gain continuity of the mandible in cases where other approaches are inadequate.
Learning Objectives:
- Specific straight forward techniques, dosages to be used, and selection of allogeneic scaffolds, size, and type, will be discussed so that each attendee can incorporate In-Situ Tissue Engineering (ITSE) in their practice.
The New Face of Osteonecrosis of the Jaws. How to Diagnose, Prevent and Treat it – Thursday, October 15, 2020, 4:15 pm – 6:15 pm
Drug Induced Osteonecrosis (DION) is now the official AMA ICD-10 code M87.10 named for a disease recognized by the dental profession since 2003. What is new is that in addition to bisphosphonates causing DIONJ in both the osteoporosis and cancer patient RANK-Ligand inhibitors are also causing DIONJ and in many cases sooner and more severe.
For the dental profession, preventative dentistry measures, control of inflammation and especially occlusal balance has emerged as effective prevention schemes that an reduce the incidence of DIONJ in both the osteoporosis and cancer patient.
For the osteoporosis patient a nine month drug holiday for an oral bisphosphonate or a four month unrestricted application of dental implants, teeth extractions osseous periodontal procedures, crown lengthening etc.
For the cancer patients, drug holidays only apply to the bisphosphonate naïve patient on a RANNK-Ligand inhibitor. Treatment in each group can be nonsurgical with specific antibiotic protocols or surgical with procedures ranging from sequestrectomy to alveolar resections to continuity resections depending upon the stag of DIONJ, symptoms, dysfunction, and goals of the patient.
Learning Objectives
- To learn the diagnosis, prevention, and treatment differences between those caused by bisphosphonates and RANL-Ligand inhibitors.
- To learn the effectiveness of drug holidays for osteoporosis patients.
- To learn the best history questions, clinical assessments, and radiographic clues in assessing ONJ.
- To actively participate in prevention and treatment of ONJ patients with either osteoporosis or metastatic cancer.
Robert E. Marx is Professor of Surgery and Chief of the Division of Oral and Maxillofacial Surgery at the University of Miami Miller School of Medicine, and is well known as an educator, researcher, and innovative surgeon. He has pioneered new concepts and treatments for pathologies of the oral and maxillofacial area as well as new techniques in reconstructive surgery.
His many prestigious awards, including the Harry S. Archer Award, the William J. Giles Award, the Paul Bert Award, the Donald B. Osbon Award, and the Daniel Laskin Award, attest to his dedication and commitment to the field of oral and maxillofacial surgery.
His textbook “Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment” has also won the American Medical Writers Associations Prestigious Book of the year Award and his other textbooks “Platelet Rich Plasma: Dental and Craniofacial Applications”, “Tissue Engineering”, “Oral and Intravenous Bisphosphonates Induced Osteonecrosis”, and an “Atlas of Bone Harvesting” have been best sellers. He is a section editor of Oral and Craniofacial Tissue Engineering and serves as a reviewer to many journals.